{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:04:50Z","timestamp":1789859090501,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.ctarc.2019.100123","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T14:10:30Z","timestamp":1550931030000},"page":"100123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1)"],"prefix":"10.1016","volume":"19","author":[{"given":"Omar","family":"Najim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Huizing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Bich","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Goethals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zwaenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Weyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevilay","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebren","family":"Tjalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctarc.2019.100123_bib0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/ctm.ctm_10_17","article-title":"The application of estrogen receptor-1 mutations\u2019 detection through circulating tumor DNA in breast cancer","volume":"3","author":"Liu","year":"2017","journal-title":"Cancer Transl. Med."},{"key":"10.1016\/j.ctarc.2019.100123_bib0002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156802606776173483","article-title":"Estrogen receptors as therapeutic targets in breast cancer","volume":"6","author":"Ariazi","year":"2006","journal-title":"Curr.Top. Med. Chem."},{"issue":"40","key":"10.1016\/j.ctarc.2019.100123_bib0003","doi-asserted-by":"crossref","first-page":"66901","DOI":"10.18632\/oncotarget.11383","article-title":"Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole","volume":"8","author":"Gyanchandani","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctarc.2019.100123_bib0004","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-15-0943","article-title":"ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients","volume":"22","author":"Chu","year":"2016","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.ctarc.2019.100123_bib0005","first-page":"19","article-title":"The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer","author":"Jeselsohn","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ctarc.2019.100123_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/GCO.0000000000000039","article-title":"The renaissance of endocrine therapy in breast cancer","volume":"26","author":"Williams","year":"2014","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"October (10)","key":"10.1016\/j.ctarc.2019.100123_bib0007","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"June (2)","key":"10.1016\/j.ctarc.2019.100123_bib0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new antioestrogenic agent in late breast cancer. an early clinical appraisal of ICI46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2019.100123_bib0009","first-page":"6929","article-title":"ICI 164, 384: a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness","volume":"49","author":"Thompson","year":"1989","journal-title":"Cancer Res."},{"issue":"April","key":"10.1016\/j.ctarc.2019.100123_bib0010","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1074\/jbc.M510809200","article-title":"Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha","volume":"281","author":"Long","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2019.100123_bib0011","first-page":"214","article-title":"Endocrine therapy for advanced breast cancer","volume":"12","author":"Shah","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"March (1)","key":"10.1016\/j.ctarc.2019.100123_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(24)01479-0","article-title":"Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance","volume":"53","author":"Clarke","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ctarc.2019.100123_bib0013","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.mce.2013.04.026","article-title":"Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling","volume":"382","author":"Magnani","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ctarc.2019.100123_bib0014","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000354757","article-title":"Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase\/akt\/ mammalian target of rapamycin signaling pathway","volume":"8","author":"Hassona","year":"2013","journal-title":"Breast Care"},{"key":"10.1016\/j.ctarc.2019.100123_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2016.11.001","article-title":"ESR1 mutations: moving towards guiding treatment decision-making in metastatic breast cancer patients","volume":"52","author":"Angus","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2019.100123_bib0016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","article-title":"Endocrine resistance in breast cancer- an overview and update","volume":"418","author":"Clarke","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"August (4)","key":"10.1016\/j.ctarc.2019.100123_bib0017","first-page":"e6565","article-title":"Are estrogen receptor genomic aberrations predictive of hormone therapy response in breast cancer?","volume":"9","author":"Tabarestani","year":"2016","journal-title":"Iran. J. Cancer Prev."},{"key":"10.1016\/j.ctarc.2019.100123_bib0018","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.breast.2013.09.006","article-title":"Co-targeting estrogen receptor and HER2 pathways in breast cancer","volume":"23","author":"Mehta","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.ctarc.2019.100123_bib0019","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1373\/clinchem.2015.238717","article-title":"Noninvasive Detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor\u2013positive metastatic Breast cancer","volume":"61","author":"Guttery","year":"2015","journal-title":"Clin. Chem."},{"issue":"March (5)","key":"10.1016\/j.ctarc.2019.100123_bib0020","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1078-0432.CCR-15-1534","article-title":"Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients","volume":"22","author":"Wang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2019.100123_bib0021","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.clinbiochem.2013.06.002","article-title":"A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR","volume":"46","author":"Norton","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ctarc.2019.100123_bib0022","doi-asserted-by":"crossref","first-page":"32504","DOI":"10.18632\/oncotarget.8839","article-title":"Clinical significance of monitoring ESR1 mutations in circulating cell-freeDNA in estrogen receptor positive breast cancer patients","volume":"7","author":"Takeshita","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2019.100123_bib0023","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"issue":"313","key":"10.1016\/j.ctarc.2019.100123_bib0024","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ctarc.2019.100123_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12498","article-title":"Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers","volume":"7","author":"Miller","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829421830159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829421830159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:17:44Z","timestamp":1762841864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829421830159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":25,"alternative-id":["S246829421830159X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2019.100123","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2019.100123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100123"}}